Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | An overview of the main challenges to prolonging remission in AML

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, highlights the main challenges clinicians face in prolonging remission in acute myeloid leukemia (AML). To reduce relapses, it is crucial to have treatments that are well-tolerated when given over long periods of time. Finding this balance between efficacy and safety, to ensure the disease is being targeted but the patient is not harmed, is another challenge to prolonging remission. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.